HASTINGS DAVID C 4
4 · Arbutus Biopharma Corp · Filed Feb 3, 2023
Insider Transaction Report
Form 4
HASTINGS DAVID C
Chief Financial Officer
Transactions
- Award
Common Shares
2023-02-01+79,000→ 79,000 total - Award
Stock Option (Right to Buy)
2023-02-01+316,000→ 316,000 totalExercise: $2.90Exp: 2033-02-01→ Common Shares (316,000 underlying)
Footnotes (2)
- [F1]Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
- [F2]This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.